GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Cash Flow from Others
中文

Alphamab Oncology (HKSE:09966) Cash Flow from Others

: HK$-127.9 Mil (TTM As of Jun. 2023)
View and export this data going back to 2019. Start your Free Trial

Alphamab Oncology's cash flow from others for the six months ended in Jun. 2023 was HK$-79.7 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-127.9 Mil.


Alphamab Oncology Cash Flow from Others Historical Data

The historical data trend for Alphamab Oncology's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Others
Get a 7-Day Free Trial 574.91 16.03 6.32 -92.25 -

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.31 -46.24 -48.21 -79.68 -

Alphamab Oncology Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-127.9 Mil.

Alphamab Oncology Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Alphamab Oncology (HKSE:09966) Business Description

Traded in Other Exchanges
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines